Notes
The study was funded by Gilead Sciences Srl.
Reference
Ruggeri M, et al. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. Applied Health Economics and Health Policy : 24 Jul 2018. Available from: URL: http://doi.org/10.1007/s40258-018-0410-x
Rights and permissions
About this article
Cite this article
Sofosbuvir/velpatasvir for early-stage HCV infection cost effective. PharmacoEcon Outcomes News 809, 36 (2018). https://doi.org/10.1007/s40274-018-5188-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5188-4